More serious but less common risks include pancreatitis, gallbladder problems including gallstones, kidney issues including acute kidney failure in patients who experience severe vomiting or diarrhea, changes in vision, low blood sugar especially when combined with other diabetes medications, and increased heart rate
After propensity-score matching, the two cohorts (26,784 in each cohort, mean age 51.3 years, 65.6% women, 16.1% Black, 66.5% White, 6.7% Hispanic) were balanced (Table 1)
The drug is presently in Phase III obesity clinical trials and is expected to launch by 2027
More time under tension produces a stronger hypertrophy stimulus at the same load
Finding the sweet spot takes practice but becomes automatic within a few weeks
What this means if youre on Mounjaro or Wegovy In the short term, the TRIUMPH-1 results dont change anything practical for people currently taking Mounjaro or Wegovy